|
|
|
|
| LEADER |
01551nam a2200277 u 4500 |
| 001 |
EB002001300 |
| 003 |
EBX01000000000000001164201 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Dicyclomine for gastrointestinal conditions
|h Elektronische Ressource
|b a review of the clinical effectiveness, safety, and guidelines
|c prepared by Canadian Agency for Drugs and Technologies in Health
|
| 246 |
3 |
1 |
|a Dicyclomine for GI conditions
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 03 December 2015, 2015
|
| 300 |
|
|
|a 1 PDF file (10 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Gastrointestinal Diseases / drug therapy
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Muscarinic Antagonists / therapeutic use
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK350056
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a This Rapid Response report aims to review the clinical effectiveness and safety of dicyclomine for gastrointestinal (GI) conditions. Evidence-based guidelines associated with the use of dicyclomine in the management of GI conditions will also be examined
|